ASBP Company Profile and Key Details

ASBP has shown weak momentum, losing -47.11% over the past week and -85.24% over the past quarter, though year-to-date performance is down -61.9%. Short-term trend indicators are bullishly aligned (SMA20 -2.65%, SMA50 -46.36%, SMA200 -86.42%). The stock’s 14-day RSI is 39.56 (weak momentum), while the ATR of 0.31 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -98.07% below its high and over 20.83% above its low. Average 10-day trading volume of 1.02 million shares is significantly above the 3-month average of 477.24 thousand, indicating heightened recent market interest.

Aspire Biopharma Holdings, Inc. has 5.02 million shares outstanding. The public float is 2.33 million shares, elevated short interest at 17.83% of float. This equals 750.20 thousand shares. The short ratio is 0.5 days. Institutional investors hold 3.67% of the float. Insiders own 20.77%.

Aspire Biopharma Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.25. This means the shares are trading below this model’s fair value.

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) closed at $5.25 USD, gaining $0.08 (1.55%) from the previous close of $5.17. The stock is currently mid-range between its 52-week high and low $0.11 and $35.00. With a market capitalization of about $605.70 thousand, Aspire Biopharma Holdings, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.21). Key stats such as the average daily volume over the past year has been around 13.64 million shares, volume is running light vs its 52-week average. Headquartered in Estero, FL, Aspire Biopharma Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kraig T. Higginson, the company employs approximately 2 people and listed since February 20, 2025. Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States.

Aspire Biopharma Holdings, Inc. trades at a P/E ratio of -0.32, slightly below the S&P 500 average, with a price-to-sales ratio of 96.17 and a price-to-book ratio of -1.21 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.12, also below market averages.

Our AI price prediction model suggests that Aspire Biopharma Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by May 26, 2026, within a range of $0.00 to $7.74 3-Month Outlook: Projected fall of -62.09%, reaching $1.96 by August 10, 2026, with a range of $0.00 to $39.33. 1-Year Outlook: Projected loss of -99.42%, with price at $0.03 by May 12, 2027, within a range of $0.00 to $49.00.

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) shares are down -61.9% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Aspire Biopharma Holdings, Inc. trading at a premium to the broader market with a P/E of -0.32. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term fall (-62.09% over three months), and a longer-term loss (-99.42% over one year), with expected trading ranges indicating moderate volatility.